Reinforcing aerosol cisplatin for radiotherapy of laryngeal cancer.
To attain its increased tumor concentration and to avert its systemic adverse effects, aerosol cisplatin (CDDP) was incorporated into radiotherapy (RT) of laryngeal cancer. Nine patients were asked to inhale the aerosol following each RT session. Their clinical tumor response was favorable, and histopathologic survey in selected cases revealed elimination of viable cancer cells. However limited, there have been no reports of cancer recurrence yet. This reinforcing plan of aerosol CDDP for RT bleomycin would certainly offer a better way of treating laryngeal cancer, and probably those malignancies facing the nasopharyngobronchial airway as well.
Okuyama
S
S
Department of Radiology, Tohoku Rosai Hospital, Sendai.
Matsumoto
K
K
Saijo
S
S
Suetake
M
M
Yuasa
R
R
Mishina
H
H
D000336:Aerosols; D000368:Aged; D001761:Bleomycin / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006801:Humans; D007822:Laryngeal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged
D000336:Aerosols; D001761:Bleomycin; D002945:Cisplatin